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ABSTRACT
Objective To describe the long term costs, health
benefits, and cost effectiveness of laparoscopic surgery
compared with those of continued medical management
for patients with gastro-oesophageal reflux disease
(GORD).
DesignWe estimated resource use and costs for the first
year on the basis of data from the REFLUX trial. A Markov
model was used to extrapolate cost and health benefit
over a lifetime using data collected in the REFLUX trial and
other sources.
Participants The model compared laparoscopic surgery
and continued proton pump inhibitors in male patients
aged 45 and stable on GORD medication.
Intervention Laparoscopic surgery versus continued
medical management.
Main outcome measuresWe estimated quality adjusted
life years and GORD related costs to the health service
over a lifetime. Sensitivity analyses considered other
plausible scenarios, in particular size and duration of
treatment effect and the GORD symptoms of patients in
whom surgery is unsuccessful.
Main results The base case model indicated that surgery
is likely to be considered cost effective on averagewith an
incremental cost effectiveness ratio of £2648 (€3110; US
$4385) per quality adjusted life year and that the
probability that surgery is cost effective is 0.94 at a
threshold incremental cost effectiveness ratio of £20000.
The results were sensitive to some assumptions within
the extrapolation modelling.
Conclusion Surgery seems to be more cost effective on
average than medical management in many of the
scenarios examined in this study. Surgery might not be
cost effective if the treatment effect does not persist over
the long term, if patients who return to medical
management have poor health related quality of life, or if
proton pump inhibitors were cheaper. Further follow-up of
patients from the REFLUX trial may be valuable.
Trial registration ISRCTN15517081.
INTRODUCTION
Around 25% of adults in Western society experience
intermittent heartburn, one of the cardinal symptoms
of gastro-oesophageal reflux disease (GORD).1 2 Once
diagnosed with erosive (persistent) GORD, patients
often require lifelong pharmacotherapy, usually pro-
ton pump inhibitors.3 Although considered effective,
there are concerns about the long term side effects of
proton pump inhibitors, and expenditure on these
drugs remains considerable, despite recent reductions
in prices. In general practice in England expenditure
was £233m (€274m; US$386m) in 2007.4 Laparo-
scopic fundoplication is now an alternative way to
treat GORD. In addition to potential clinical benefits
laparoscopic surgery should lead to the avoidance of
continual medication and its associated costs. Several
studies have examined economic characteristics of
laparoscopic surgery.5-8 Of those that compared sur-
gery with GORD medication, Bojke8 found that sur-
gery was cost effective, and Cookson6 concluded that
laparoscopic surgery had similar costs tomedicalman-
agement after eight years and was cost saving there-
after. Arguedas evaluated the strategies in a United
States setting and concluded that medical therapy
dominated surgery using a 10 year time horizon,
assuming a higher rate of symptom recurrence and
re-operation after surgery than in the surgery groups
in the UK based studies.5 None of these studies, how-
ever, used estimates of health related quality of life
derived from a randomised clinical trial comparing
laparoscopic fundoplication with medical manage-
ment, which is of central importance to the evaluation
of these treatments. This paper updates the economic
study by Bojke8 to incorporate one year health related
quality of life data from the REFLUX trial.9
The multicentre REFLUX trial compared a strategy
of laparoscopic surgery with one of continued medical
management for patients with reasonable symptom
control on GORD medications.9 The clinical and
patient assessed outcomes of the trial up to one year
after surgery have recently been reported. Although
these findings showed clear benefits of surgery at this
time in terms of health related quality of life, decision
makers are also interested in the costs and cost effec-
tiveness of the two forms of management. GORD is
usually a chronic condition and a key issue is the extent
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to which benefits are sustained. Surgery is costly in the
short term, but these costs may be at least partly offset
by reductions in lifetime use of GORD medication.
Extrapolation of health benefits and costs are thus
needed to provide a meaningful estimate of cost effec-
tiveness.
METHODS
Overview
Weused amodel comparing laparoscopic surgery and
continued use of proton pump inhibitors in male
patients aged 45 (the median age and predominant
sex in the REFLUX trial9), and stable on anti-GORD
medication. Over a lifetime horizon, health benefits
were quantified in terms of quality adjusted life years
and costs were assessed from the perspective of the
United Kingdom’s NHS in 2008/2009 prices. Future
costs and health benefits are discounted (adjusted to
current values) at 3.5% per year, in accord with UK
guidelines for economic evaluation.10
Model structure
Figure 1 shows themodel structure. It is a discrete time
Markov cohort model with a cycle length of one year.
Patients follow a strategy of either early laparoscopic
surgery or continuation ofmedicalmanagement (with-
out the option of surgery after failure of medical man-
agement).
In the model, surgery may “fail” in one of two ways.
Patients may need revision of surgery, either to
improve symptom control or because of surgical com-
plications, or theymay return to use of long termmed-
ical management because of continued symptoms.11
This model assumes that patients in the medical
management arm are stable on GORD medication.
This assumption follows the inclusion criteria for the
REFLUX trial. As a result “treatment failure” is not
defined as a health state in the model. Annual costs of
medical management are estimated using mean con-
sumption of proton pump inhibitors during the
REFLUX trial, incorporating any changes to dose or
medication, and it is assumed that the estimate of
health related quality of life includes, on average,
remission or any side effects of medication. The base
case assumes that, if surgical patients do not need to
return to medical management or need revision of
surgery, the relative difference in health related quality
of life of surgery over medical management will be
maintainedover their lifetime.Weused sensitivity ana-
lyses to consider other scenarios where the treatment
effect (the difference in health related quality of life
between medical management and those who do not
fail surgery) only lasts for one, two, or five years. In
these alternative scenarios, health related quality of
life is the same in the surgery group as in the medical
management group after the “treatment effect” ends,
even in patients who do not return to the use of proton
pump inhibitors.
Evidence used in the model
Costs for the first year in the model were estimated
from the REFLUX trial.9 The trial collected data on
use of health service resources up to one year, includ-
ing inpatient days in hospital wards and high depen-
dency units, diagnostic tests, duration in theatre,
outpatient and general practitioner visits, re-admis-
sions, and use of GORD medication. These resources
were costed using routine NHS unit costs and prices
(table 1).
We calculated rates of return to medical manage-
ment and revision of surgery using data from the
REFLUX trial and studies identified through a litera-
ture search.8 12 The average rate of return to medical
management overall was 4.9 per 100 person years
and the average rate of revision of surgery was 0.8
per 100 person years, although rates seemed to vary
considerably between studies. As we did not find evi-
dence that this variationwas related to length of follow-
up, we assumed that the annual rate of surgical failure
was constant over time. Details of the literature
searches and meta-analyses are available in the Health
Technology Assessment monograph.12 Sensitivity
analyses were undertaken assuming higher and lower
rates of failure.
After the first year, all patients require an annual visit
to their general practitioner. It was assumed that
patients who fail surgery need an additional visit to
their general practitioner and to a hospital specialist.
No hospital admissions or outpatient visits for
GORD related reasons were included after one year
for patients with successful surgery.13
Patients can die of other causes,14 and the model
assumed the same age and sex specific risk of mortality
as the UK general population. Although no deaths
from surgery or revision occurred in the REFLUX
trial, a small additional risk of operative mortality was
assumed, estimated by a meta-analysis (four deaths in
4000 procedures).8
Estimating quality adjusted life years
The REFLUX trial measured health status using the
genericEuroQolEQ-5D instrument.15 Eachof the pos-
sible 243 health states was mapped to a preference
based value (or “utility”) where zero represents a state
equivalent to death and one represents full health.16
Table 1 shows the mean differences in utility between
treatments at one year estimated by the REFLUX
Treatment decision
Medical management
Re-operateMedical management
Surgery
Die, any cause Die, any cause
Fig 1 | Model structure
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trial.12 No other randomised trials have compared sur-
gery with medication using a preference based mea-
sure of health related quality of life.
We assumed that the “adjusted treatment received”
analysis of the REFLUX trial12 was the most appropri-
ate measure of the effect of surgery on health related
quality of life to use in the base case model. This
approach identifies the efficacy of surgery in patients
who are most likely to comply with their clinicians’
recommendations for treatment.17 18 We also used
intention to treat and per protocol estimates in sensitiv-
ity analyses.
In the model, we use the term “treatment effect” to
refer to the difference in health related quality of life
between medical management and those who do not
fail surgery. This value differs from the estimates calcu-
lated in the trial, which measured the mean difference
in health related quality of life between medical man-
agement and surgery, whether failed or not. As those
who fail surgery would be expected to have lower
health related quality of life than those who do not,
this approach estimates a lower bound for the benefits
of surgery by the model.
We estimated the health related quality of life of the
15 patients in the surgery group of the REFLUX trial
who required proton pump inhibitors at one year to be
0.68 (standard error 0.048) using the EQ5D, a decrease
of 0.04 from baseline. In view of the small sample of
patients and short follow-up, it was assumed in the base
case analysis that patients who needed proton pump
inhibitors after surgery returned to their baseline
(pre-surgery) health related quality of life, consistent
with clinical opinion (Robert Heading, personal com-
munication, 2008) that proton pump inhibitors are just
as effective after surgery as before, provided they are
being used to treat reflux symptoms. This assumption
was varied in sensitivity analysis.
To account for the decline in health related quality of
life with age, the mean utility for medical management
observed at the end of the REFLUX trial was com-
pared with the average utility for the general popula-
tion aged 45-5519 to calculate a proportionate
decrement in utility for that health state. It was
assumed that this proportionate decrement was con-
stant as the cohort aged (table 1).
Analysis
We did calculations using Excel. The model estimated
mean costs and quality adjusted life years in each treat-
ment cohort. Where one treatment did not dominate
the other, the incremental cost effectiveness ratio was
calculated as the ratio of the difference in expected
costs to the difference in expected quality adjusted
life years. A probabilistic sensitivity analysis was
done by assigning probability distributions to the
model inputs, rather than treating them as point
estimates.20 This analysis calculated the overall uncer-
tainty in the treatment decision as the proportion of
simulations where laparoscopic surgery is cost effec-
tive, given threshold values for the incremental cost-
effectiveness ratio of £20 000 and £30 000 per quality
Table 1 | Health related quality of life (HRQOL) estimates and rates of events used in model
Parameter Mean (SE)* Distribution for PSA Source
HRQOL
HRQOL while on medical management,
or return to medical management
0.711 (0.018) Gamma† Baseline EQ5D of patients
randomised in REFLUX trial12
Additional HRQOL after successful laparoscopic
surgery compared with medical management
Adjusted treatment received‡ 0.068 (0.038) Normal REFLUX12
Intention to treat§ 0.047 (0.026) Normal REFLUX12
Per protocol¶ 0.076 (0.028) Normal REFLUX12
HRQOL for general male population
Aged 45-55 0.84 Kind 199919
Aged 55-65 0.78 Kind 199919
Aged 65-75 0.78 Kind 199919
Aged 75+ 0.75 Kind 199919
Rates of events
Return to medical management after surgery 460 events,
9389 patient years
Gamma Meta-analysis12
Revision of surgery 53 events,
6720 patient years
Gamma Meta-analysis12
Operative mortality 4 deaths, 3397 patients Beta Meta-analysis8
SE=standard error, PSA=probabilistic sensitivity analysis.
*Unless otherwise indicated.
‡Adjusted treatment received is estimated by linear model using treatment received indicator variable as a covariable. The residual of regression of
treatment received on the randomisation indicator variable is included as another covariable to adjust for confounders.17 This is the base case used
in the model.
§Intention to treat is the mean difference between randomised groups adjusting for body mass index, age, sex, and baseline score.
¶Per protocol is the difference between the randomised groups using only participants who received their allocated GORD management adjusting for
BMI, age, sex, and baseline score.
†The decrement in HRQOL (utility) on medical management compared with the general age-matched population is parameterised in the stochastic
model by a gamma distribution with a mean of 1-0.711 and a standard error of 0.018.
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adjusted life year as used by the National Institute of
Health and Clinical Excellence.10
RESULTS
Table 2 shows the use of health service resources and
cost for GORD related causes during the first year of
follow-up in theREFLUX trial, 12 for patients receiving
their randomised treatment per protocol. Total costs
were £370 per patient in the medical management
arm and £2709 in the surgical arm, a difference of
£2339 (95% confidence interval 2147 to 2558; calcu-
lated with bias corrected accelerated bootstrap). 21
Under base case assumptions, the model predicts
that, for example, by five years 17.7% of surgery
patients will have returned to medical management,
2.9% will have undergone a re-operation, and 0.1%
will have died during surgery. The average discounted
lifetime cost per patient of surgerywas £5026,made up
of the initial cost of the cost of surgery (£2132), repair of
surgery (£746), return tomedicalmanagement (£1360)
and other health care (£788). The discounted lifetime
cost of the medical management group was £3411.
Therefore, surgery had an additional mean cost of
£1616. The mean difference in quality adjusted life
years was 0.61, equating to an incremental cost effec-
tiveness ratio of £2648 per quality adjusted life year
(table 3, scenario 1). In the base case, the probability
that surgery is cost effective at a cost effectiveness
threshold of £20 000 is 0.94.
We explored several scenarios regarding the size
and duration of treatment effect, GORD symptoms
of those who fail surgery and costs (table 3). Use of
intention –to treat and per protocol estimates of effect
did not change the conclusion that surgery is cost effec-
tive assuming a threshold of £20 000 per quality
adjusted life year gained. The probability that surgery
is cost effective decreases to 0.77 if patients who return
to proton pump inhibitors have worse GORD symp-
toms than before surgery (scenario 7). Surgery is unli-
kely to be cost effective if it is assumed that its benefits
(in termsof health related quality of life relative tomed-
ical management) are notmaintained beyond one year
(scenario 4).
Surgerymight also not be cost effective in somemul-
tivariate sensitivity analyses. For example, the incre-
mental cost effectiveness ratio increases to about
£22 000 if proton pump inhibitors can be effectively
delivered at half the cost estimated here—perhaps
due to greater use of lower cost drugs—and there is
no difference in health related quality of life after two
years (scenario 16).
DISCUSSION
Principal findings
Under base case assumptions, surgery is cost effective
on average with an incremental cost-effectiveness ratio
of £2648 per quality adjusted life year. The probability
of surgery being cost effective is high given a threshold
of £20 000 per quality adjusted life year and assuming
the treatment effect lasts for at least five years and
patients who fail surgery do not have worse symptoms
than before surgery.
The results of this analysis are similar to those of
Bojke8 who also found surgery to be cost effective.
That model was constructed using baseline utility
data from the REFLUX trial but did not include the
treatment effect of surgery at one year.
Strengths and weaknesses of this study
We have compared the cost effectiveness of laparo-
scopic surgery with that of medical management
Table 2 | Mean use of healthcare resources and costs for GORD related causes in REFLUX trial12 for patients receiving their
randomised treatment per protocol and followed up for one year
Unit
cost
(£) Source* Unit of measure
Medical (n=155) Surgery (n=104)
Any use
(%)
Mean
use
Mean
cost (£) SD (£)
Any use
(%)
Mean
use
Mean
cost (£) SD (£)
Endoscopy 172 a Tests — — — — 88 0.88 151 57
pH tests 64 a Tests — — — — 70 0.70 45 29
Manometry 61 a Tests — — — — 66 0.66 40 29
Operation time 4 a Minutes — — — — 100 114.5 420 137
Consumables 825 a — — — — — 100 1.00 825 0
Ward 264 b Days — — — — 100 2.34 619 354
High dependency 657 b Days — — — — 1 0.05 32 322
Total surgery — — — — — — — — — 2132 475
Visit to GP 36 c Visits 44 1.16 42 71 44 1.14 42 60
Visit from GP 58 c Visits 1 0.01 1 6 2 0.02 1 8
Outpatient 88 b Visits 14 0.30 27 76 43 0.54 47 64
Day case 896 b Admit 10 0.14 127 426 42 0.47 422 572
Inpatient 1259 b Admit 3 0.03 32 200 4 0.04 48 243
Subsequent costs — — — — — 229 632 — — 560 728
Medication costs — d — — — 141 144 — — 16 52
Total costs — — — — — 370 638 — — 2709 941
*Sources of unit costs used in the analysis: (a) Mean unit costs of a survey of five participating centres, 2003, updated for inflation,8 (b) mean
hospital costs for England and Wales, 2006/07,25 (c) Curtis et al, 2008,26 (d) British National Formulary, 200924 and REFLUX.12
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using randomised data on the effect of treatment on
health related quality of life.
The REFLUX trial was a pragmatic study and the
results, in terms of symptom control and health related
quality of life, are expected to be generalisable to
patients in the UK who are stable on GORD medica-
tion and suitable for surgery.22 Nevertheless, because
rates of surgical reintervention and return to medical
management in clinical practice might differ from the
trial or with longer follow-up,23 we have used mean
rates from a literature review to inform this analysis.
In the base case we used the “adjusted treatment”
received estimate of the treatment efficacy. Intention
to treat and per protocol estimates were also used in
sensitivity analyses. The intention to treat analysis is
an unbiased estimate of effectiveness but is diluted by
the high proportion (38%) of patients in the REFLUX
trial who were randomised to surgery but did not
receive it.12 The most common reason given for non-
compliance was patient choice, which was thought to
be affected by long waiting times.12 Given that waiting
times vary between centres and over time, the inten-
tion to treat estimate in the REFLUX trial might not
be generalisable to current practice in the NHS. The
per protocol analysis adjusting for baseline age, sex,
bodymass index, andEQ-5D score is anothermeasure
of the efficacy of surgery12 but using regression to
adjust for observed baseline characteristics may not
adequately control for selection bias. Regardless of
whether an adjusted treatment received, intention to
treat or per protocol analysis is conducted, surgery
appears to be cost effective at the thresholds used by
NICE (National Institute for Health and Clinical
Excellence), if it is assumed that health related quality
of life is maintained over the long term.
Costs of medication were calculated using current
pack prices24 applied to the prescribing pattern
observed in REFLUX.12 Some evidence indicates
that prescribers have been switching to lower cost pro-
ton pump inhibitors such as lansoprazole or omepra-
zole following sharp reductions in their prices in recent
years, and consequently the current cost of medical
managementmaybe lower than estimatedhere.4How-
ever, surgery remains cost effective even if the annual
cost of medication is half that in the base case, other
considerations being equal. Nevertheless, in some sce-
narios surgery is unlikely to be cost effective, particu-
larly where costs of medical management are lower
than calculated in the base case and the health related
quality of life benefit of surgery is not maintained over
the long term.
The duration of the treatment effect is, therefore, an
important but uncertain assumption. To inform this
question, follow up of REFLUX trial patients has
Table 3 | Results of base case economic model and sensitivity analyses. Expected costs and QALYs per patient in each scenario were calculated as mean of
1000 simulations using probabilistic model
Scenario
Key input values Model results
Duration
of effect
Utility difference for
successful surgery
Utility after
failure of surgery
QALY
difference
Cost
difference (£)
ICER
(£/QALY) P (20k) P (30k)
(1) Base case 20 0.068 0.711 0.61 1616 2648 0.944 0.953
Univariate (one way) sensitivity analyses
(2) ITT estimate of treatment effect 20 0.047 0.711 0.42 1616 3876 0.918 0.935
(3) Per-protocol estimate of treatment effect 20 0.076 0.711 0.68 1616 2363 0.989 0.992
(4) Treatment effect lasts 1 year 1 0.068 0.711 0.05 1616 32 534 0.204 0.429
(5) Treatment effect lasts 2 years 2 0.068 0.711 0.11 1616 14 807 0.659 0.788
(6) Treatment effect lasts 5 years 5 0.068 0.711 0.26 1616 6232 0.88 0.899
(7) Worse HRQOL after failure of surgery than MM group 20 0.068 0.680 0.37 1616 4405 0.768 0.792
(8) Higher annual probability of return to MM (11.2%) than
base case (4.9%)
20 0.068 0.711 0.42 1978 4744 0.899 0.928
(9) Higher annual probability of repair of surgery (4%) than
base case (0.8%)
20 0.068 0.711 0.63 3890 6189 0.87 0.905
(10) Higher probability of operative mortality of surgery or
repair (1%) than base case (0.1%)
20 0.068 0.711 0.46 1579 3425 0.878 0.888
(11) 100% increase in cost of surgery 20 0.068 0.711 0.61 3927 6437 0.877 0.909
(12)50%reduction inannual expenditure onPPIs compared
with base case
20 0.068 0.711 0.61 2392 3921 0.91 0.931
Multivariate (two-way and three-way) sensitivity analyses
(13) Duration of treatment effect is for five years and worse
HRQOL if fail surgery
5 0.068 0.680 0.02 1616 101 290 0.383 0.428
(14) ITT estimate and duration of treatment effect is for five
years
5 0.047 0.711 0.17 1616 9269 0.807 0.859
(15) ITT estimate and duration of treatment effect is for five
years and worse HRQOL if fail surgery
5 0.047 0.680 −0.07 1616 Dom 0.213 0.248
(16) 50% reduction in annual expenditure on PPIs and
duration of treatment effect is two years
2 0.068 0.711 0.11 2392 21 923 0.455 0.683
Dom=surgery is dominated with higher costs and lower QALYs than MM (and no ICER is calculated); HRQOL=health related quality of life, ICER=incremental cost-effectiveness ratio;
ITT=intention to treat analysis; MM=medical management; PPI=proton pump inhibitors; P(20k)=probability surgery is cost effective at a cost-effectiveness threshold of £20 000; P(30k)=
probability surgery is cost effective at a cost-effectiveness threshold of £30 000.
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been extended to five years. Given the results of the
trial so far and the assumptions made in the decision
model, extending the follow up of the trial from one
year (scenario 4) to five years (scenario 6) would
increase the probability that surgery is cost effective
at a threshold of £20 000 per quality adjusted life year
from 0.20 to 0.88. However, under more pessimistic
assumptions about health related quality of life of
patients who return to medical management, then
even five years of follow-up would still leave consider-
able uncertainty about the value of surgery.
Conclusions
Although surgery seems likely to be cost effective in
terms of expected (mean) costs and health effects,
uncertainty remains about the duration of the treat-
ment effect and the severity of GORD symptoms
after failure of surgery. Furthermore, a number of prac-
tical issues need to be considered before the NHS
could offer surgery to all patients who are currently
stable on medical management. In particular, surgical
capacity and availability of trained surgeons are poten-
tial barriers to implementation that would need to be
addressed.
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